Research Article

Evaluation of the Diagnostic Sensitivity of the VIASURE Leishmania Real-Time PCR Detection Kit Prototype for the Diagnosis of Cutaneous and Visceral Leishmaniasis

Albert Arnau,1,2 Alba Abras,2 Cristina Ballart,1,3 Anna Fernández-Arévalo,1 Mary Cruz Torrico,1,4 Silvia Tebar,1 Teresa Llovet,5,6,7 Montserrat Gállego,1,3,8 and Carmen Muñoz5,6,7

1 Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain
2 Àrea de Genètica, Departament de Biologia, Universitat de Girona, Girona, Spain
3 Institut de Salut Global de Barcelona (ISGlobal), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
4 Facultad de Medicina, Universidad Mayor de San Simón (U.M.S.S.), Cochabamba, Bolivia
5 Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
6 Institut de Recerca Biomèdica Sant Pau, Barcelona, Spain
7 Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain
8 CIBERINFEC, ISCIII- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain

Correspondence should be addressed to Montserrat Gállego; mgallego@ub.edu and Carmen Muñoz; cmunoz@santpau.cat

Received 8 February 2023; Revised 23 October 2023; Accepted 24 November 2023; Published 18 December 2023

Copyright © 2023 Albert Arnau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Leishmaniasis is a parasitic disease with clinical presentations that vary from asymptomatic infection to cutaneous, mucocutaneous, or visceral disease. Global change, with migratory movements and travels, among others, has had an impact on the presentation of the clinical forms of leishmaniasis in a given area, hindering its diagnosis. The traditional parasitological techniques have limited sensitivity, and currently, there is no reference or gold-standard molecular diagnostic method. The aim of this study was to evaluate the effectiveness of the VIASURE Leishmania Real-Time PCR Detection Kit prototype (CerTest Biotec, Zaragoza, Spain) for the diagnosis of autochthonous and imported leishmaniasis in comparison with two other commercialized molecular kits: STAT-NAT® Leishmania spp. (Sentinel, Milano, Italy) and Leishmania spp. Real-TM PCR Kit (Sacace Biotechnologies, Como, Italy). Four species of Leishmania, L. infantum, L. major, L. braziliensis, and L. panamensis, were targeted to assess analytical sensitivity, whereas diagnostic sensitivity was evaluated by studying a panel of 49 DNA samples from patients with suspected or confirmed Leishmania infection. The prototype could detect all the New and Old World species studied and achieved a limit of detection of 5 × 10^{-5} ng DNA/μL in all species. Also, it allowed the diagnosis of autochthonous and imported cases of cutaneous and visceral leishmaniasis (VL). Diagnostic sensitivity was 81.8% for the prototype and 100% for the Sacace kit (27 and 33 positive samples detected, respectively). The STAT-NAT® kit failed to detect Vianna species. The VIASURE Leishmania Real-Time PCR Detection Kit prototype was found to have good analytical and diagnostic sensitivity. Using a simple protocol and ready-to-use reagents, results are obtained quickly and are easy to interpret. The evaluation results indicate that the test is a promising candidate for routine diagnosis of cutaneous leishmaniasis and VL in endemic countries, but more studies are necessary to address its sensitivity and specificity.

1. Introduction

Leishmaniasis is a vector-borne disease caused by protozoan parasites from the genus Leishmania, which are transmitted by the bite of infected female sandflies of the genera Phlebotomus and Lutzomyia [1, 2]. According to the World Health Organization, leishmaniasis is one of the seven most important tropical diseases worldwide. In 2020, it was described as endemic in large areas of the tropics, being...
present in around 98 countries and territories in all continents except Oceania [1].

About 20 species of *Leishmania* have been identified as pathogenic for humans [3], and they cause three main clinical variants of the disease: (i) cutaneous leishmaniasis (CL), with infected macrophages resident in the skin; (ii) mucosal leishmaniasis, which affects mucous membranes of the nose, mouth and throat; (iii) and visceral leishmaniasis (VL), with infected mononuclear phagocytic cells in the liver, spleen, bone marrow, lymphatics nodes, and intestine [3, 4].

The most common form is CL, with about 600,000 to 1 million new cases occurring annually worldwide [1]. CL is characterized by epithelial lesions and ulcers in exposed regions of the body [5]. The cutaneous, mucosal, and mucocutaneous forms of leishmaniasis, collectively referred to as tegumentary leishmaniasis (TL), are not usually fatal. The cutaneous forms of leishmaniasis, collectively referred to as tegumentary leishmaniasis (TL), are not usually fatal. The most severe form is VL, with 50,000 to 90,000 new cases reported per year [1]. Without treatment, VL is fatal in most severe form is VL, with 50,000 to 90,000 new cases reported per year [1]. Without treatment, VL is fatal in 95% of cases and, even when treated, is associated with case-fatality rates of 10%–20% [6, 7]. All the *Leishmania* species infecting humans can cause CL, whereas the species known to cause VL belong to the *L. donovani* complex [4, 8].

The diagnosis of leishmaniasis relies on clinical manifestations and epidemiological and laboratory data [9, 10]. In the absence of a gold-standard diagnostic test, different combinatorial algorithms are used. Methods to detect *Leishmania* infection include microscopy, *in vitro* culture, serology, dermal diagnostic tests, xenodiagnosis, and molecular approaches [11–14]. Each method has its advantages, and its usefulness may vary according to the clinical form of the disease [15–17].

Recently, several molecular tools have been developed for the diagnosis of leishmaniasis, and they are playing an increasingly relevant role in this field due to their high sensitivity, specificity, and applicability to a variety of clinical samples [13]. Molecular methods are also useful for monitoring treatment response in patients with leishmaniasis and other diseases [18, 19]. Among them, quantitative real-time PCR (qPCR) is increasingly the method of choice, as it is fast, has a broad dynamic range, and drastically reduces carryover contamination because there is no need to open reaction tubes for post-PCR analyses [13, 20, 21].

In some endemic areas, including countries of South America, leishmaniasis is caused by a wide variety of coexisting *Leishmania* species [3, 10, 22], whereas in others, such as Spain, only one autochthonous species is involved; nevertheless, with increased population movement associated with globalization, cases are being imported from South America, the Maghreb, and elsewhere [23]. The difficulty of designing an optimal method to detect all the circulating species hampers the diagnosis of the disease. Commercial molecular kits are available mainly for the diagnosis of VL, and very few allow the detection of all species capable of causing TL. CerTest Biotec (Zaragoza, Spain) has recently developed a prototype qPCR assay to detect and diagnose infection by *Leishmania* spp. in patients with signs of TL or VL. This prototype was designed to avoid time-consuming manipulation steps, thus reducing the risk of contamination, by incorporating lyophilized reagents for the qPCR assay.

In this context, the aim of this study was to perform a comparative analysis of three molecular diagnostic kits for leishmaniasis: the new VIASURE *Leishmania* Real-Time PCR Detection Kit prototype (CerTest Biotec, Zaragoza, Spain) and the commercialized STAT-NAT® *Leishmania* spp. (Sentinel, Milano, Italy) and *Leishmania* spp. Real-TM PCR Kit (Sacace biotechnologies, Como, Italy) kits.

### 2. Materials and Methods

#### 2.1. Leishmania Strains

To evaluate the analytical sensitivity of the diagnostic methods, four strains of four species of *Leishmania* were targeted. They belonged to the subgenus *Leishmania* from the Old World (*L. infantum* and *L. major*) and subgenus *Viannia* from the New World (*L. braziliensis* and *L. panamensis*). The strains were isolated from patients with CL or VL and cryopreserved in the Cryobanc of Trypanosomatids (Universitat de Barcelona). Before the analysis, the strains were thawed and cultured on Schneider’s insect medium supplemented with 20% fetal bovine serum and 1% sterile human urine [23].

The DNA extraction from cryopreserved strains was carried out with a manual extraction kit for tissue samples (High Pure PCR Purification Kit of Roche, Basel, Switzerland) following the manufacturer’s instructions. The extracted DNA was stored properly at −20°C until use. The DNA of the strains was quantified with a NanoDrop 1,000 Spectrophotometer (Waltham, Massachusetts, United States). DNA concentration was adjusted to around 50 ng/µL of *Leishmania* DNA for each species, and 1/10 serial dilutions up to 5 × 10^−6 ng/µL were carried out in the elution buffer supplied with the DNA extraction kit (Roche). The *Leishmania* strains were characterized by hsp70 gene sequencing and MALDI-TOF MS [23].

#### 2.2. DNA Samples

For the diagnostic sensitivity study, a panel of 49 DNAs was used, previously isolated from clinical samples of patients with suspected or culture-confirmed leishmaniasis without any clinical or epidemiological criteria. The panel of clinical samples consisted of 44 DNAs from skin biopsy samples and five DNAs from visceral clinical samples (one from peripheral blood, one from liver biopsy, and three from bone marrow aspiration). The DNA of clinical samples was obtained retrospectively using two different methods: the aforementioned manual extraction kit (Roche) and an advanced automated instrument with the EZ1 DNA Tissue or EZ1 DNA Blood Kits (Qiagen, Hilden, Germany). The extracts were stored at −20°C until analysis. The *Leishmania* isolates were obtained and characterized prior to the study.

#### 2.3. Molecular Assays

The performance of the new prototype (VIASURE *Leishmania* Real Time PCR Detection Kit, CerTest) was compared with that of two commercial CE-marked kits already available for the molecular diagnosis of leishmaniasis: (i) the STAT-NAT® *Leishmania* spp. Kit (Sentinel Diagnostics), and (ii) the *Leishmania* spp. Real-TM PCR Kit (Sacace Biotechnologies). All the qPCR reactions were carried out in a QuantStudio 6 qPCR Flex system (Applied Biosystems, Waltham, Massachusetts, United States). All
samples were tested in duplicate, including the positive and negative controls supplied by the respective kit, in each run.

The VIASURE kit is a prototype multiplex qPCR method designed for the detection of *Leishmania* spp. in different biological samples from patients with signs and symptoms of leishmaniasis using the 18S rRNA gene as a target. The amplification conditions were: one cycle at 2′ at 95°C, 45 cycles of 10′ at 95°C and 50′ at 60°C. The kit can be stored at room temperature. The results were analyzed using the software of the real-time PCR equipment according to the manufacturer’s instructions. A sample was considered positive when the cycle threshold (Ct) value obtained was less than 40 (web page of the Certest prototype for more information https://www.certest.es/wp-content/uploads/2021/07/VIASURE_LEI_ES.pdf).

The STAT-NAT® (Sentinel) kit is a qualitative multiplex test based on qPCR amplification using fluorescent probes specific for *Leishmania* spp. According to the manufacturer’s manual, the assay is able to detect all *Leishmania* species in whole blood samples. The kit allows room-temperature transport and storage. A sample was considered positive when the Ct value obtained was less than 40.

The Sacace kit is a qualitative diagnostic test, which, according to the manufacturer’s manual, is able to detect all *Leishmania* species in tissue specimens such as skin sores (for CL) or bone marrow (for VL). The kit needs to be stored at −20°C. The extraction control could only be added in the assays with cryopreserved strains and not in the clinical analysis, which was carried out directly with stored DNAs. A sample was considered positive when the Ct value obtained was less than 40.

The Sacace kit is a qualitative diagnostic test, which, according to the manufacturer’s manual, is able to detect all *Leishmania* species in tissue specimens such as skin sores (for CL) or bone marrow (for VL). The kit needs to be stored at −20°C. The extraction control could only be added in the assays with cryopreserved strains and not in the clinical analysis, which was carried out directly with stored DNAs. A sample was considered positive when the Ct value obtained was less than 40.

2.4. Data Analysis. The criteria for interpreting the test results were the following: samples were classified as positive when a confirmatory positive result was obtained by culture and/or by the commercial Sacace kit and were considered negative when a negative result was obtained with both techniques.

The following measures of diagnostic accuracy were calculated (TP, true positive; TN, true negative; FP, false positive; FN, false negative): sensitivity (calculated as TP/(TP + FN) × 100); specificity (calculated as TN/(TN + FP) × 100), positive and negative predictive values (PPV and NPV, respectively), which are the proportion of correctly diagnosed individuals with positive (PPV) or negative (NPV) results (calculated as TP/(TP + FP) × 100 and TN/(TN + FN) × 100, respectively), and the prevalence (calculated as (total positive/total samples) × 100). Calculations were performed with the software VassarStats, which is available online at http://vassarstats.net.

3. Results

3.1. Linearity of the Assays and Limit of Detection. The Ct values obtained for each assay carried out with different 10-fold dilutions of DNA isolated from the four cultured *Leishmania* species are shown in Figure 1.

The results obtained with the VIASURE prototype could detect all the New and Old World species studied at all the dilution ranges tested in duplicate. Similar results were obtained by the Sacace kit, with the exception of the last dilution point of *L. infantum*, when none of the duplicates were detected. In contrast, the STAT-NAT® kit failed to detect the New World species *L. braziliensis* and *L. panamensis*, although its Ct values for the Old World *Leishmania* species were lower (Figure 1).

3.2. Clinical Evaluation. The clinical performance of the STAT-NAT® kit was not assessed, as it failed to detect *V. infantis* species. According to the criteria of positivity, 33 out of the 49 samples analyzed were considered positive and 16 negatives (Table 1). The VIASURE prototype achieved a total of 27 qPCR-positive results, whereas the Sacace kit gave positive results in 33 samples. All the positive DNA samples detected by VIASURE were positive by Sacace, but not vice versa. The global results are shown in Table 2, including previous data based on culture methods and the characterization of the species. All the samples with positive cultures tested positive with both assessed kits (VIASURE and Sacace). When using VIASURE, 23 skin biopsies and four samples from VL patients were positive, compared to 28 skin biopsies and five VL samples with Sacace. Both kits showed similar Ct values in positive samples.

The diagnostic accuracy of the VIASURE prototype is shown in Table 3, being the sensitivity of 81.8%.

4. Discussion

In Spain, as in other countries of the Mediterranean basin, *L. infantum* is the only autochthonous species that causes VL and CL, including nontypical forms and mucosal involvement [23, 24]. Increased population movements have altered the etiology and distribution of leishmaniasis, which has become increasingly common, including in nonendemic countries [23]. Imported cases of leishmaniasis have been reported in Spain and other Mediterranean countries, especially of CL, involving infection by *Leishmania* species from both the New and Old World [8, 25–28].

According to the WHO, CL incidence in the EU countries affected by leishmaniasis increased significantly in the periods 2005–2008 and 2017–2020 (e.g., from 0.01 to 0.27 in France and from 0.03 to 0.4 in Spain). In contrast, VL has increased in parts of the European Mediterranean region but insignificantly. It should be stressed that CL is not a mandatory reportable disease in many countries, which affects the accuracy of the incidence rate, as many positive diagnoses of *Leishmania* patients are lost. The number of imported cases and the growing incidence in this endemic region could have serious implications for disease management due to an unnoticed spread of nonautochthonous leishmaniasis, increased treatment failure, and development of resistance to treatments [29, 30].

Thus, in the clinical context, there is a pressing need to establish optimized protocols for the detection and identification of all potential etiological agents of leishmaniasis, as this would allow a more accurate prognosis and efficient treatment [23, 31]. In the present work, we assessed the analytical sensitivity of the VIASURE *Leishmania* Real-Time PCR...
Detection Kit prototype for the detection of the autochthonous *L. infantum* and species from countries of the Old World (*L. major*) and New World (*L. braziliensis* and *L. panamensis*) in comparison with two commercial CE-certified kits: Sacace *Leishmania* spp. Real-TM PCR and Sentinel STAT-NAT® *Leishmania* spp.

The traditional diagnosis of leishmaniasis relies on the microscopic detection of the amastigote form of the parasite in stained samples and *Leishmania* culture, but newer techniques based on PCR assays offer greater sensitivity [32–34]. Of the 49 samples in our study, 13 were positive by culture isolation, whereas 27 and 33 tested positive by the VIASURE and Sacace qPCR kits, respectively. In the case of the STAT-NAT® kit, only DNA samples from CL patients from the Old World and VL cases were positive.

As the causative agents of VL are the species belonging to the *L. donovani* complex [24, 33], its molecular diagnosis is more straightforward compared to TL, which is caused by a wider variety of *Leishmania* species. Designing and standardizing a PCR method for TL diagnosis with sufficient sensitivity and specificity has been a significant challenge due to the requirement of targeting multiple species [20, 21]. Accordingly, we found that the STAT-NAT® kit was sensitive for VL diagnosis, as shown by the Ct obtained, but could not detect CL caused by New World species (see Figure 1).

Overall, PCR-based methods are accessible, safe, have improved/good sensitivity, and provide reliable results in routine laboratory conditions [13]. Another advantage is that parasite culture is not required, and the tests may be applied directly to clinical samples [35]. qPCR assays have been implemented for DNA detection, quantification of parasite burden, and species typing using different targets and protocols. Compared to standard PCR protocols, they are more sensitive and require a simpler standardization procedure [12, 21].

**TABLE 1:** Final results of the VIASURE *Leishmania* Real-Time PCR Detection Kit according to the interpretation criteria (see Section 2.4).

<table>
<thead>
<tr>
<th>Commercial Sacace kit</th>
<th>Pos</th>
<th>Neg</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIASURE kit prototype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pos</td>
<td>27</td>
<td>0</td>
<td>27</td>
</tr>
<tr>
<td>Neg</td>
<td>6</td>
<td>16</td>
<td>22</td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
<td>16</td>
<td>49</td>
</tr>
</tbody>
</table>

**FIGURE 1:** Comparison of the Ct values obtained with the three different kits for *Leishmania* infantum, *L. major*, *L. braziliensis*, and *L. panamensis*. Values correspond to the mean of the duplicates for each dilution.
<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Culture</th>
<th>VIASURE Ct</th>
<th>SACACE Ct</th>
<th>Clinical form/sample</th>
<th>Species identification**</th>
<th>Sample ID</th>
<th>Culture</th>
<th>VIASURE Ct</th>
<th>SACACE Ct</th>
<th>Clinical form/sample</th>
<th>Species identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neg</td>
<td>36.944</td>
<td>35.852</td>
<td>CL/SB</td>
<td></td>
<td>26*</td>
<td>Neg</td>
<td>28.818</td>
<td>28.950</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>27</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
</tr>
<tr>
<td>3</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>28</td>
<td>Neg</td>
<td>36.274</td>
<td>35.693</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>29</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>30*</td>
<td>Pos</td>
<td>16.299</td>
<td>16.664</td>
<td>CL/SB</td>
<td>L. infantum</td>
</tr>
<tr>
<td>6</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>31</td>
<td>Neg</td>
<td>32.437</td>
<td>33.767</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Pos</td>
<td>21.028</td>
<td>19.867</td>
<td>CL/SB</td>
<td>L. braziliensis</td>
<td>32*</td>
<td>Neg</td>
<td>33.370</td>
<td>34.922</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>8*</td>
<td>Neg</td>
<td>31.401</td>
<td>31.326</td>
<td>CL/SB</td>
<td></td>
<td>33</td>
<td>Neg</td>
<td>38.231</td>
<td>38.497</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>34</td>
<td>Pos</td>
<td>33.476</td>
<td>32.940</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>10*</td>
<td>Neg</td>
<td>32.812</td>
<td>33.210</td>
<td>CL/SB</td>
<td></td>
<td>35</td>
<td>Neg</td>
<td>Neg</td>
<td>37.799</td>
<td>CL/SB</td>
<td>L. panamensis</td>
</tr>
<tr>
<td>11</td>
<td>Neg</td>
<td>Neg</td>
<td>37.669</td>
<td>CL/SB</td>
<td></td>
<td>36</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>12*</td>
<td>Pos</td>
<td>20.922</td>
<td>23.568</td>
<td>CL/SB</td>
<td>L. infantum</td>
<td>37*</td>
<td>Neg</td>
<td>33.867</td>
<td>31.056</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>13*</td>
<td>Pos</td>
<td>18.029</td>
<td>21.003</td>
<td>CL/SB</td>
<td>L. infantum</td>
<td>38</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>14*</td>
<td>Neg</td>
<td>39.649</td>
<td>36.799</td>
<td>CL/SB</td>
<td></td>
<td>39</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>15*</td>
<td>Pos</td>
<td>24.630</td>
<td>25.873</td>
<td>CL/SB</td>
<td>L. infantum</td>
<td>40</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>16*</td>
<td>Pos</td>
<td>28.131</td>
<td>28.439</td>
<td>CL/SB</td>
<td>L. major</td>
<td>41*</td>
<td>Pos</td>
<td>26.841</td>
<td>29.345</td>
<td>CL/SB</td>
<td>L. infantum</td>
</tr>
<tr>
<td>17</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
<td>42</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>18*</td>
<td>Pos</td>
<td>27.005</td>
<td>27.643</td>
<td>CL/SB</td>
<td>L. major</td>
<td>43</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Neg</td>
<td>36.215</td>
<td>37.171</td>
<td>CL/SB</td>
<td></td>
<td>44</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
<td>CL/SB</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Neg</td>
<td>37.315</td>
<td>37.171</td>
<td>CL/SB</td>
<td></td>
<td>46*</td>
<td>Pos</td>
<td>22.668</td>
<td>22.829</td>
<td>VL/BM</td>
<td>L. infantum</td>
</tr>
<tr>
<td>22</td>
<td>Neg</td>
<td>34.787</td>
<td>32.655</td>
<td>CL/SB</td>
<td></td>
<td>47*</td>
<td>Pos</td>
<td>29.201</td>
<td>27.664</td>
<td>VL/BM</td>
<td>L. infantum</td>
</tr>
<tr>
<td>23</td>
<td>Neg</td>
<td>29.512</td>
<td>28.445</td>
<td>CL/SB</td>
<td></td>
<td>48*</td>
<td>Pos</td>
<td>32.353</td>
<td>32.874</td>
<td>VL/PB</td>
<td>L. infantum</td>
</tr>
<tr>
<td>24</td>
<td>Neg</td>
<td>25.604</td>
<td>23.391</td>
<td>CL/SB</td>
<td></td>
<td>49*</td>
<td>Neg</td>
<td>Neg</td>
<td>36.435</td>
<td>VL/BM</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Neg</td>
<td>25.604</td>
<td>23.391</td>
<td>CL/SB</td>
<td></td>
<td>Total POS</td>
<td>13/49</td>
<td>27/49</td>
<td>33/49</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CL: cutaneous leishmaniasis, VL: visceral leishmaniasis, SB: skin biopsy, BM: bone marrow, LB: liver biopsy, PB: peripheral blood; *Positive result by the STAT-NAT® Leishmania spp. Kit (Sentinel, Milano, Italy). ** Characterization was done by hsp70 gene sequencing and MALDI-TOF MS [21].
Currently, there is no consensus on a universal protocol for the molecular diagnosis of leishmaniasis, and various molecular targets for *Leishmania* identification have been described for conventional and real-time PCR assays, such as kDNA, ITS-1, SSU, and *hsp70* [20, 36–39]. Although several in-house qPCR assays have been developed, very few studies have focused on validating commercial PCR-based kits for leishmaniasis diagnosis in humans, which are useful for routine laboratory testing. To obtain the necessary certification for marketing, these diagnostic tools need validation by independent studies. In the present study, the STAT-NAT® kit showed better analytical sensitivity than the VIASURE and Sacace kits for the subgenus *Leishmania* (*L. infantum* and *L. major*) but failed to detect species of the New World subgenus *Viannia* (*L. braziliensis* and *L. panamensis*). Consequently, it was not used for clinical evaluation. Similar Ct values were obtained with the VIASURE and Sacace kits, and the detection limit of both tests was comparable, even for analytical sensitivity and specificity. Sacace had a higher diagnostic sensitivity and detected more positive samples (33 versus 27 by the prototype). Nevertheless, as indicated in Section 2, when using the Sacace kit, the extraction control was not added to the clinical samples, as these had been prepared prior to the study, which was retrospective in nature. This could have affected the sensitivity of the assay, as a monoplex reaction is carried out when there is no extraction control. Different studies report reduced sensitivity in multiplex versus monoplex qPCR assays when using samples with a low amount of DNA and high Ct values [40, 41].

The prototype has been able to diagnose both autochthonous and imported cases of CL and VL, which are increasing in the Mediterranean region, caused by different species of *Leishmania* [23, 25]. It is also worth noting that the patient’s epidemiological context and clinical symptoms are very important parameters for the development of treatment once the *Leishmania* infection has been diagnosed. The therapeutic regimen will depend on the clinical presentation, the host’s condition, the species causing the infection, and the size of the lesion, among other variables [8–30].

In routine care diagnosis, it is important that results are obtained quickly, using a simple protocol and ready-to-use reagents, and are easy to interpret. Designed to meet these requirements, the VIASURE *Leishmania* Real-Time PCR Kit prototype comes in an 8-strip tube format, in which all the reagents needed for the multiplex qPCR are lyophilized, which allows room temperature transport and storage. After applying a hydration buffer, provided by the manufacturer, only the DNA sample needs to be added to the solution before starting the reaction, avoiding time-consuming manipulation steps, thus reducing the risk of contamination. In contrast, the Sacace *Leishmania* spp. Real-TM PCR Kit comes with different vials for each reagent, and buffer is needed for the qPCR, which clearly lengthens the sample preparation time, and storage must be at −20°C. Interpretation of results was similarly straightforward in both assays.

One of the goals of this study was to assess how the VIASURE kit would behave in routine diagnostic testing for *Leishmania* in different biological samples. This was done using a panel of DNAs from patients with suspected infection by *Leishmania* and different clinical manifestations (CL and VL), as well as DNA extracted from biological samples (45 from skin biopsies, three from bone marrow, one from a liver biopsy, and one from peripheral blood). Both kits were able to detect *Leishmania* in both visceral and cutaneous samples, regardless of the source (autochthonous or imported cases and different human clinical samples).

Notably, one of the limitations of commercialized PCR kits is they do not allow species-specific detection of *Leishmania*. Therefore, future research could focus on developing a single multiplex qPCR assay that is able to differentiate between the most common causal species of human CL.

### 5. Conclusion

The evaluation results of the VIASURE *Leishmania* Real-Time PCR Detection Kit prototype indicate that the test is a promising candidate for routine diagnosis of CL and VL in endemic countries. However, more studies are necessary to address its sensitivity and specificity.

### Data Availability

There are no supporting data in this article.

### Disclosure

CerTest Biotec, S.L. supplied the prototype used in the study but had no role in the design of the study, data collection, analyses, writing of the manuscript, or decision to publish the results. The initial findings of this work were presented at the 31st European Congress of Clinical Microbiology and Infectious Diseases in July 2021, as a poster.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Authors’ Contributions

Authors Alba Abras, Cristina Ballart, and Anna Fernández-Árêvalo contributed equally to the work. Authors Montserrat Gállego and Carmen Muñoz should be considered as joint senior authors.
Acknowledgments

The authors would like to thank the Drugs for Neglected Diseases Initiative (DNDi) for donating the qPCR equipment. Specific funding has not been received for this study. The participating UB and ISGlobal investigators are part of the GREPIMER group (Grup de Recerca en Patologia Importada i Malalties Emergents i Re-emergents), which received support from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 924). ISGlobal research was supported by the Tropical Disease Cooperative Research Network (RITC) (RD12/0018/010) and by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program.

References


